BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at the Deutsche Bank 32nd Annual Health Care Conference
Franklin, Tenn. – April 30, 2007 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that Dr. Charles E. Hart, chief scientific officer, will provide an update of corporate activities at the Deutsche Bank 32nd Annual Health Care Conference. The presentation will take place at the Mayflower Hotel in Washington D.C. on Thursday, May 3 at 2:30 p.m. Eastern Time. A live audio webcast of the presentation will be available at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=BMTI&item_id=1499383 and on the Company's website at www.biomimetics.com. The webcast will be accessible for a period of at least 30 days. About BioMimetic TherapeuticsBioMimetic Therapeutics, Inc. is developing and commercializing bio-active protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, periodontal, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product, GEM 21S ®, as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of its platform technology in this indication. Additionally, the Company has clinical trials ongoing for multiple orthopedic bone healing indications. The Company's product and product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration. For further information, visit www.biomimetics.com or contact Kearstin Patterson, corporate communications, at 615-236-4419.
Back to Headlines |
